ライフサイエンスコーパス: oesophageal

1 ociated with an increased risk of developing oesophageal (1.38, 1.06-1.80), gastric (1.36, 1.03-1.79)

2 and 3.29, 2.59-4.18, with multiple myeloma), oesophageal (1.96, 1.46-2.64), lung (1.82, 1.52-2.17) ki

3 one patient in the 0.5% once daily group had oesophageal achalasia), all of which were unrelated to s

4 ce monitoring often reveals more significant oesophageal acid exposure than impedance-measured reflux

5 ratified by patient position and compared to oesophageal acid exposure time (AET).

6 Oesophageal adenocarcinoma (EAC) incidence is rapidly in

7 E), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in whic

8 Oesophageal adenocarcinoma (OAC) is increasing in incide

9 Oesophageal adenocarcinoma (OAC) is one of the most comm

10 lux disease (GORD)-Barrett's metaplasia (BM)-oesophageal adenocarcinoma (OAC) model.

11 ration are significant prognostic factors in oesophageal adenocarcinoma (OAC), however no reliable pr

12 by whole genome sequencing (WGS) studies in oesophageal adenocarcinoma (OAC).

13 Lactobacillus fermentum was enriched in oesophageal adenocarcinoma (p=0.028), and lactic acid ba

14 (rs9823696) was associated specifically with oesophageal adenocarcinoma (p=1.6 x 10(-8)) and was inde

15 dysplastic Barrett's oesophagus [n=23], and oesophageal adenocarcinoma [n=19]), relevant negative co

16 known risk loci for Barrett's oesophagus and oesophageal adenocarcinoma and revealed new insights int

17 ssociations between hypertension and risk of oesophageal adenocarcinoma and squamous cell carcinoma,

18 urthermore, the specific association between oesophageal adenocarcinoma and the locus near HTR3C and

19 ociation studies of Barrett's oesophagus and oesophageal adenocarcinoma available in PubMed up to Feb

20 Patients with surgically resectable oesophageal adenocarcinoma classified as stage cT1N1, cT

21 herapy can rapidly and profoundly affect the oesophageal adenocarcinoma genome.

22 known as Barrett's oesophagus can evolve to oesophageal adenocarcinoma in decades-long processes of

23 The strongest risk factor for oesophageal adenocarcinoma is reflux disease, and the ri

24 Oesophageal adenocarcinoma represents one of the fastest

25 and neck squamous-cell carcinoma, or gastro-oesophageal adenocarcinoma that had relapsed or was refr

26 There was decreased microbial diversity in oesophageal adenocarcinoma tissue compared with tissue f

27 rrett's oesophagus and 4112 individuals with oesophageal adenocarcinoma, in addition to 17 159 repres

28 ing the genetics of Barrett's oesophagus and oesophageal adenocarcinoma, we aimed to identify novel g

29 arrett's oesophagus is the main precursor to oesophageal adenocarcinoma, which has a poor prognosis.

30 the development of Barrett's oesophagus and oesophageal adenocarcinoma, which might encourage develo

31 t predisposes patients to the development of oesophageal adenocarcinoma, which, once invasive, carrie

32 atic, HER2-positive, PD-L1-unselected gastro-oesophageal adenocarcinoma, with an Eastern Cooperative

33 sociated with either Barrett's oesophagus or oesophageal adenocarcinoma, within or near the genes CFT

34 y treated patients with HER2-positive gastro-oesophageal adenocarcinoma.

35 patients with MET-positive gastric or gastro-oesophageal adenocarcinoma.

36 croenvironment in seven (47%) of 15 cases of oesophageal adenocarcinoma.

37 gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.

38 gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.

39 the development of Barrett's oesophagus and oesophageal adenocarcinoma.

40 oesophagus is the premalignant precursor of oesophageal adenocarcinoma.

41 the transition from Barrett's oesophagus to oesophageal adenocarcinoma.

42 ative growth whose eradication could prevent oesophageal adenocarcinoma.

43 squamous-cell carcinoma, and 55 with gastro-oesophageal adenocarcinoma.

44 our (9%, 2-20) of 47 individuals with gastro-oesophageal adenocarcinoma; all were partial responses.

45 Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes

46 whole-exome and deep sequencing of 30 paired oesophageal adenocarcinomas sampled before and after neo

47 Oesophageal AET limits for GORD detection were utilized

48 vide new insight into the preventive role of oesophageal ALDH2 against acetaldehyde-derived DNA damag

49 ed cancer mortality, particularly for gastro-oesophageal and colorectal cancer.

50 of noxious contents of the stomach may cause oesophageal and extra-oesophageal complications either b

51 roximated to Odds Ratio for rare events) for oesophageal and gastric cancer development in bisphospho

52 sis and methylation, and may protect against oesophageal and gastric cancers.

53 nd over compared with those under 40 years); oesophageal and gastric/duodenal malignancy (48 and 32 r

54 owever, including high-grade serous ovarian, oesophageal, and small-cell lung cancer, are driven by s

55 fida [n = 7,422], encephalocele [n = 1,562], oesophageal atresia [n = 6,303], biliary atresia [n = 3,

56 lish its role for neonatal disorders such as oesophageal atresia and biliary atresia through clinical

57 resection, congenital diaphragmatic hernia, oesophageal atresia, and ruptured omphalocele or gastros

58 Survival for children with spina bifida, oesophageal atresia, biliary atresia, diaphragmatic hern

59 ncreased proliferation and aneuploidy in the oesophageal basal epithelium.

60 EoE-A children had increased iNKT levels in oesophageal biopsies compared with EoE-C children.

61 d from prospectively collected and biobanked oesophageal biopsies from 36 Caucasian treatment naive E

62 P < 0.001) and distal (2.9-fold, P < 0.001) oesophageal biopsies from EoE patients.

63 nology) was performed on proximal and distal oesophageal biopsies of 30 paediatric EoE patients and 4

64 elevated levels of IL-23 mRNA were found in oesophageal biopsies of patients with reflux oesophagiti

65 INKTs from peripheral blood (PB) and oesophageal biopsies were studied.

66 iet (<15 eosinophils per high power field at oesophageal biopsy), and who underwent food challenge wi

67 to the Rome II FGID categories of functional oesophageal, bowel and anorectal disorders, and to the s

68 circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing concurrent c

69 ccepted as a standard tool in the staging of oesophageal cancer (OC).

70 on mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar

71 cancer-susceptibility syndrome tylosis with oesophageal cancer (TOC), suggesting a role for this pro

72 ears, diagnosed with breast, colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010

73 rative effects in colonic mucosa and in some oesophageal cancer cell lines.

74 data from 150 BE and 285 EAC cases from the Oesophageal Cancer Classification and Molecular Stratifi

75 ticipants were registered (115 in the gastro-oesophageal cancer cohort, 950 in the colorectal cancer

76 ntestinal bleeding (any grade) in the gastro-oesophageal cancer cohort.

77 the recently published chemoradiotherapy for oesophageal cancer followed by surgery study trial showe

78 urgical resection for stage III or IV distal oesophageal cancer in 1987-2010 with follow-up until 201

79 ce for an increase in the risk of gastric or oesophageal cancer in bisphosphonate users and one findi

80 ost all patients who underwent resection for oesophageal cancer in Sweden in 1987-2010.

81 e of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not impro

82 rt a small but significant increased risk of oesophageal cancer in women prescribed bisphosphonates a

83 Endoscopically diagnosed oesophageal cancer increased by 32 % per decade, but gas

84 Oesophageal cancer is a clinically challenging disease t

85 c role of lymphadenectomy during surgery for oesophageal cancer is questioned.

86 a small but significantly increased risk of oesophageal cancer linked to duration of bisphosphonate

87 of Life Questionnaire-Core 30 (QLQ-C30) and -Oesophageal Cancer Module (QLQ-OES24) questionnaires pre

88 eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumou

89 odeoxyglucose ((18)F-FDG) PET images for 441 oesophageal cancer patients (split: testing = 353, valid

90 carce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and n

91 rapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.

92 Lymphadenectomy during oesophageal cancer surgery is a safe procedure in the sh

93 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for curative trea

94 ls in a collection of DNA samples taken from oesophageal cancer tissues.

95 ncluded patients with advanced or metastatic oesophageal cancer who were randomly assigned (1:1) thro

96 Thus, patients with distal oesophageal cancer with coeliac node metastasis seem to

97 itional deaths, a 4.8-5.3% increase; and for oesophageal cancer, 330 (324-335) to 342 (336-348) addit

98 er, 24 975 with colorectal cancer, 6744 with oesophageal cancer, and 29 305 with lung cancer.

99 er cardiovascular and circulatory disorders, oesophageal cancer, preterm birth complications, congeni

100 For oral, oropharyngeal and oesophageal cancer, the early detection of tumours and o

101 are the cause of the inherited cutaneous and oesophageal cancer-susceptibility syndrome tylosis with

102 , ongoing controversies, and future needs in oesophageal cancer.

103 ry as standard treatment of locally advanced oesophageal cancer.

104 ompared with surgery alone for patients with oesophageal cancer.

105 tasis precludes long-term survival in distal oesophageal cancer.

106 lignant dysphagia in patients with incurable oesophageal cancer.

107 sociation was seen with risk or survival for oesophageal cancer.

108 dence for surgery in the treatment of gastro-oesophageal cancer.

109 with placebo in previously treated advanced oesophageal cancer.

110 bleeding after radical treatment for gastro-oesophageal cancer.

111 nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent i

112 surgical removal of primary lung, breast and oesophageal cancers, low-dose adjuvant epigenetic therap

113 Two HIV-related diagnoses, oesophageal candidiasis and Kaposi's sarcoma, rose from

114 Oesophageal carcinoma affects more than 450,000 people w

115 The overall 5-year survival of patients with oesophageal carcinoma ranges from 15% to 25%.

116 Oesophageal carcinoma with associated aberrant R/subclav

117 She was found to have a oesophageal carcinoma with incidentally co-existing aber

118 us-cell carcinoma is the predominant form of oesophageal carcinoma worldwide, but a shift in epidemio

119 When associated with oesophageal carcinoma, it can cause diagnostic confusion

120 igated to improve outcomes for patients with oesophageal carcinoma.

121 ss, but also results in an increased risk of oesophageal carcinoma.

122 ive to surgery for the curative treatment of oesophageal carcinoma.

123 prevention, and advances in the treatment of oesophageal carcinoma.

124 0 years old with breast or gastric or gastro-oesophageal carcinomas refractory to standard therapy re

125 EMGdi was measured with a multipair oesophageal catheter passed per-nasally.

126 sites and affiliated genes in pre-treatment oesophageal cells between responders and non-responders

127 nd test for accelerated epigenetic ageing in oesophageal cells of EoE patients.

128 ; accelerated ageing was not observed in the oesophageal cells of healthy controls.

129 ancer therapy in four tumour cohorts: gastro-oesophageal, colorectal, breast, and prostate cancer.

130 the question of whether the peptidergic post-oesophageal commissure (POC) neurons trigger a specific

131 the stomach may cause oesophageal and extra-oesophageal complications either by direct contact of as

132 e, and has not yet been used to repair large oesophageal defects in human beings.

133 eartburn and chest pain were included in the oesophageal discomfort factor.

134 68% of the variance and these were termed: 'oesophageal discomfort', 'bowel dysfunction', 'abdominal

135 clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant infla

136 cal history is vital for distinguishing true oesophageal dysphagia from oropharyngeal dysphagia or ot

137 Oesophageal dysphagia is a so-called red flag alarm symp

138 agnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respon

139 end a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the dia

140 ying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (

141 ied disease phenotype called 'PPI-responsive oesophageal eosinophilia'.

142 and the mechanisms underlying PPI-responsive oesophageal eosinophilia.

143 ical analysis revealed significant levels of oesophageal eosinophilic infiltration (P < .05) in 4/6 o

144 iNKT levels are higher at the site of active oesophageal eosinophilic inflammation.

145 matched stem cells of Barrett's, gastric and oesophageal epithelia that yield divergent tumour types

146 sion was localised to the basal layer of the oesophageal epithelium.

147 e miRNAs localised to the basal layer of the oesophageal epithelium.

148 Elevated oesophageal expression of LTC4 S mRNA is found in a subg

149 this approach might not be representative of oesophageal function during the ingestion of normal food

150 consistent reductions were seen in risks of oesophageal, gastric, biliary, and breast cancer.

151 ofiles for muscle, nervous system, tegument, oesophageal gland, parenchymal/primordial gut cells, and

152 ode effector proteins are synthesized in the oesophageal glands and are secreted into plant tissues t

153 variants in three squamous-cell carcinomas (oesophageal, head and neck and lung) significantly promo

154 o treat the most debilitating aspect of EoE, oesophageal inflammation and remodelling.

155 ibed the first such system to arise from the oesophageal International Cancer Genome Consortium proje

156 used propofol TCI sedation during endoscopic oesophageal interventions.

157 endoscopists than propofol during endoscopic oesophageal interventions?

158 Fewer oesophageal intubations occurred in the video laryngosco

159 adenocarcinomas of the oesophagus and gastro-oesophageal junction (Siewert types 1 and 2).

160 h histologically confirmed gastric or gastro-oesophageal junction adenocarcinoma (cohorts A and B), n

161 inal pain in patients with gastric or gastro-oesophageal junction adenocarcinoma (in three [7%] of 41

162 ars or older with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progress

163 24-87 years with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progress

164 with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and non-small-cell l

165 CI 1.5-19.9) of 41 in the gastric or gastro-oesophageal junction adenocarcinoma cohort, eight (30%;

166 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after fi

167 afety run-in; n=11), one patient with gastro-oesophageal junction adenocarcinoma who received the 8 m

168 us therapy (for those with gastric or gastro-oesophageal junction adenocarcinoma) or one to three lin

169 y sepsis in a patient with gastric or gastro-oesophageal junction adenocarcinoma) was deemed related

170 oropyrimidine or both (for gastric or gastro-oesophageal junction adenocarcinoma).

171 eated 92 patients (41 with gastric or gastro-oesophageal junction adenocarcinoma, 27 with non-small-c

172 lly advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperat

173 metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperat

174 reviously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung

175 reviously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung

176 with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma.

177 n patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

178 nrolment for patients with gastric or gastro-oesophageal junction cancer has completed.

179 astic Barrett's oesophagus or stage I gastro-oesophageal junction cancer in the usual care group.

180 ruxtecan for HER2-positive gastric or gastro-oesophageal junction cancer post-trastuzumab.

181 atients with HER2-positive gastric or gastro-oesophageal junction cancer received at least one dose o

182 atients with HER2-positive gastric or gastro-oesophageal junction cancer who received trastuzumab der

183 atients with HER2-positive gastric or gastro-oesophageal junction cancer with previous trastuzumab tr

184 atients with HER2-positive gastric or gastro-oesophageal junction cancer.

185 anorectal junction) as well as in the gastro-oesophageal junction in the human gut.

186 ncer, including adenocarcinoma of the gastro-oesophageal junction).

187 , intestinal metaplasia occurs at the gastro-oesophageal junction, where stratified squamous epitheli

188 atic adenocarcinoma of the stomach or gastro-oesophageal junction.

189 atic adenocarcinoma of the stomach or gastro-oesophageal junction.

190 In transformed oesophageal keratinocytes, CD44(Low)-CD24(High) (CD44L)

191 ced ALDH2 production in both mouse and human oesophageal keratinocytes.

192 Together with TSLP and IL-23 mRNA levels, oesophageal LTC4 S mRNA may facilitate diagnosis of an E

193 iteria showed no association between EoE and oesophageal malignancy.

194 Varying extra-oesophageal manifestations were found in those with GERD

195 denoscopy (with biopsy), barium swallow, and oesophageal manometry, no obstructive cause may be found

196 bacter pylori, both of which might alter the oesophageal microbiota.

197 s a minimally invasive tool for sampling the oesophageal microbiota.

198 non-diabetics, which may be related to worse oesophageal motility and, thus, a more functional rather

199 high-resolution manometry (HRM) to diagnose oesophageal motility disorders is based on ten single wa

200 Diagnosis of oesophageal motility disorders was based on the Chicago

201 , 194, 203, 205 and 215 expression levels in oesophageal mucosa from individuals without pathological

202 of 10 TDFs from OAC with 12 NDF from normal oesophageal mucosa using Infinium HumanMethylation450 Be

203 ellular localisation of microRNAs within the oesophageal mucosa was determined using in-situ hybridis

204 d following transfection of a human squamous oesophageal mucosal cell line (Het-1A).

205 on has been proposed to underlie the loss of oesophageal neurons, particularly in genetically suscept

206 ly, inactivation of NANOG in cell lines from oesophageal or head and neck squamous cell carcinomas (E

207 herefore, recruitment of patients with lower oesophageal or junctional tumours planned for an oesopha

208 sitive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer.

209 EoE patients are in risk of oesophageal perforation, if so, management may be conser

210 Oesophageal pressure, diaphragm electromyography, and se

211 ient across the upper airway (estimated with oesophageal pressure, Pes) during polysomnography in fou

212 oscopic dilatations, and for advanced cases, oesophageal reconstruction.

213 Gastro-oesophageal reflux (GER) and microaspiration have been p

214 Gastro-Oesophageal Reflux (GOR) is a key problem in Cystic Fibr

215 the detection and characterization of gastro-oesophageal reflux (GOR), yet the two modalities frequen

216 eceived either standard management of gastro-oesophageal reflux (usual care group), in which particip

217 5 levels were significantly higher in gastro-oesophageal reflux compared with controls.

218 Scales for aiding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been evaluate

219 Information about gastro-oesophageal reflux disease (GERD) in patients with Diabe

220 Treatment-refractory gastro-oesophageal reflux disease (GERD) remains a significant

221 Although gastro-oesophageal reflux disease (GORD) is a common medical co

222 phageal symptoms and the aetiology of gastro-oesophageal reflux disease (GORD) remains unclear.

223 tion to neoplastic progression in the gastro-oesophageal reflux disease (GORD)-Barrett's metaplasia (

224 activity in patients with symptomatic gastro-oesophageal reflux disease (GORD).

225 The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is i

226 carriers, and a higher prevalence of gastro-oesophageal reflux disease and blistering/desquamating s

227 Approximately 20% have gastro-oesophageal reflux disease and this can be effectively t

228 Gastro-oesophageal reflux disease is a potential risk factor fo

229 failure, sleep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression.

230 s) is a pathological manifestation of gastro-oesophageal reflux disease, and is a major risk factor f

231 evelopment of non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug tre

232 be similar to those of patients with gastro-oesophageal reflux disease.

233 ing acid-suppressants for symptoms of gastro-oesophageal reflux for more than 6 months, and had not u

234 gnosis and treatment of abnormal acid gastro-oesophageal reflux in each trial.

235 Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic

236 ts) for patients with IPF, in the absence of oesophageal reflux or symptoms.

237 patients with IPF, and abnormal acid gastro-oesophageal reflux seems to contribute to disease progre

238 from individuals without pathological gastro-oesophageal reflux to individuals with ulcerative oesoph

239 is test to patients on medication for gastro-oesophageal reflux would increase the detection of Barre

240 hypertension, digital ulceration, and gastro-oesophageal reflux, are now treatable.

241 ement of IPF comorbidities, including gastro-oesophageal reflux, pulmonary hypertension, coronary art

242 In patients with gastro-oesophageal reflux, the offer of Cytosponge-TFF3 testing

243 ation in response to injury caused by gastro-oesophageal reflux.

244 epithelium as an adaptive response to gastro-oesophageal reflux.

245 RNA gene amplicon sequencing was done on 210 oesophageal samples from 86 patients representing the Ba

246 Comparison of oesophageal sampling methods showed that the Cytosponge

247 A tissue-engineered oesophageal scaffold could be very useful for the treatm

248 We consider the presented tissue-engineered oesophageal scaffolds a significant step towards the cli

249 ngth 120 mm) to bridge a 5 cm full-thickness oesophageal segment destroyed by a mediastinal abscess a

250 Lower oesophageal sphincter (LES) pressure was higher in patie

251 ute to laryngeal vestibule closure and upper oesophageal sphincter opening during swallowing.

252 stalsis and impaired relaxation of the lower oesophageal sphincter.

253 e inhibitors have efficacy in EGFR-amplified oesophageal squamous cell carcinoma (ESCC), but may beco

254 anol-derived definite carcinogen that causes oesophageal squamous cell carcinoma (ESCC).

255 lder with unresectable advanced or recurrent oesophageal squamous cell carcinoma (regardless of PD-L1

256 Oesophageal squamous cell carcinoma is a deadly disease

257 Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-ter

258 in previously treated patients with advanced oesophageal squamous cell carcinoma, and might represent

259 gnostic factor in patients with unresectable oesophageal squamous cell carcinoma.

260 in patients with previously treated advanced oesophageal squamous cell carcinoma.

261 Subjects included 498 oesophageal squamous cell carcinomas (OSCCs), 255 gastri

262 aracterised by replacement of reflux-damaged oesophageal squamous epithelium with a columnar intestin

263 Ulceration of the oesophageal squamous mucosa (ulcerative oesophagitis) is

264 As that are differentially expressed between oesophageal squamous mucosa and Barrett's oesophagus muc

265 location and function of these microRNAs in oesophageal squamous mucosa from individuals with ulcera

266 R-145 and miR-205 expression was observed in oesophageal squamous mucosa of individuals with ulcerati

267 ed definitive CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to

268 pproximately half of the world's 500,000 new oesophageal squamous-cell carcinoma (ESCC) cases each ye

269 iated, including head and neck, cervical and oesophageal, squamous cell carcinomas display loss of ZN

270 Oesophageal stents have several well-known respiratory c

271 ential for mouth opening during feeding, and oesophageal striated muscle (OSM), which is crucial for

272 Pharyngo-oesophageal stricture (PES) is a serious complication th

273 fractory dysphagia due to malignant proximal oesophageal strictures.

274 If unrecognized and injured during oesophageal surgery, it can lead to disastrous complicat

275 t underdiagnosed complication of gastric and oesophageal surgery.

276 taking HRT rely on self-reporting of gastro-oesophageal symptoms and the aetiology of gastro-oesopha

277 re further questioned and examined for extra-oesophageal symptoms of GERD.

278 ients who were referred for investigation of oesophageal symptoms were recruited at Nottingham Univer

279 establish motility disorders as the cause of oesophageal symptoms.

280 PFO+ subjects had a higher oesophageal temperature (T(oesoph)) (P < 0.05) than PFO-

281 n (n = 6) underwent passive heating until an oesophageal temperature of 2 degrees C above resting was

282 asound), cerebral oxygen delivery (CDO(2) ), oesophageal temperature, and arterial blood gases during

283 h passive hyperthermia of up to +2 degrees C oesophageal temperature, and this response was unaffecte

284 At +2.0 degrees C oesophageal temperature, arterial PCO2 was restored to n

285 nt, identify relevant food allergens, obtain oesophageal tissue non-invasively and induce tolerance w

286 to be involved with antigen presentation) on oesophageal tissue prior to, and following food antigen

287 Their levels in oesophageal tissue, however, do not distinguish patients

288 comitant with higher serum IgE levels and an oesophageal transcriptome indicative of a more-pronounce

289 PARP1 and to detect oral, oropharyngeal and oesophageal tumours in mice, pigs and fresh human biospe

290 d in the treatment of premalignant and early oesophageal tumours.

291 s with advanced breast and gastric or gastro-oesophageal tumours.

292 the 86 patients who underwent endoscopy was oesophageal varices (57%), followed by peptic ulcer dise

293 gastrointestinal-endoscopy (UGIE) identifies oesophageal varices (OV).

294 The presence of oesophageal varices does not correlate with age, sex, di

295 ollapse [possibly related to sunitinib], one oesophageal varices haemorrhage [possibly related to sun

296 tinib group (one case each of renal failure, oesophageal varices haemorrhage, circulatory collapse, w

297 readmission due to UGIB in 4 patients (2.4%) Oesophageal varices was the most common cause of UGIB.

298 Oesophageal varices were the commonest finding in patien

299 channels in respect of age, sex, presence of oesophageal varices, and the diameter of the paraumbilic

300 hannels was found in groups with and without oesophageal varices.